Examples
Worked examples
- Is an instance
A multi-site Phase III trial reaches last patient last visit at a given site. Within the sponsor's specified window, the CRA conducts the close-out visit: confirms every open query in the EDC system is resolved or has a documented resolution plan, performs a final drug accountability reconciliation against the pharmacy log, confirms the site has returned or destroyed unused investigational product per protocol, reviews the Investigator Site File against the TMF index for completeness, and confirms the investigator has sent (or has a dated plan to send) the trial's outcome summary to the IRB/REB as required by ICH E6(R2) Section 4.13.
- Is an instance
A sponsor stops a trial early after an independent data monitoring committee recommends termination for futility. Because participation ends abruptly rather than at a pre-planned LPLV, the close-out visit at each active site is scheduled promptly rather than on the trial's original close-out timeline, but it still covers the same four elements -- query resolution, IP reconciliation/disposition, essential document completeness, and IRB/REB notification of closure -- since ICH E6(R2) does not relax those requirements for an early-terminated site.
Counter-examples
Looks similar, but isn't
- Not an instance
A routine visit midway through enrollment where the CRA performs Source Data Verification, checks IP storage conditions, and reviews the Investigator Site File is an Interim Monitoring Visit (IMV), not a COV -- even though it overlaps with several of the same checklist items -- because the site is still actively enrolling or following participants and the visit does not attempt final query resolution, IP disposition, or IRB closure notification. A site only has one COV, at the true end of its participation; it can have many IMVs before that point.
Editorial commentary
A Close-Out Visit (COV) is the final monitoring visit a sponsor or its Clinical Research Associate (CRA) conducts at a clinical trial site once the site has finished its part in a study — whether that end point is the site’s last participant’s last visit (LPLV), the trial’s planned conclusion, or an early termination. It closes out the Site Initiation Visit (SIV) and Interim Monitoring Visit (IMV) sequence: every active site has exactly one SIV, some number of recurring IMVs, and exactly one COV.
What ICH E6(R2) requires a close-out visit to confirm
ICH E6(R2) Section 5.18 (Monitoring) does not use the industry term “close-out visit” itself — like Site Initiation Visit and Interim Monitoring Visit, COV is well-established clinical-operations convention layered on top of the guideline’s general monitoring obligations, not ICH-mandated terminology. What ICH E6(R2) does specify is the substance a final visit has to close out. Section 5.18.4 lists the monitor’s review activities, and industry GCP training consistently frames the closing item as: a final close-out of a trial can only occur once the monitor has reviewed both investigator/institution and sponsor files and confirmed all necessary documents are in the appropriate files. In practice that review spans: outstanding data queries resolved (or a documented plan for any that genuinely cannot be resolved); investigational product accountability finalized and IP returned or destroyed per protocol and sponsor instruction, consistent with the supply/handling/retrieval obligations at Section 5.14; and the site’s essential documents — per the Section 8 essential-documents list — complete and filed in the Trial Master File (TMF), including current IRB/REB approvals, signed protocol/amendments, and monitoring visit reports. Separately, ICH E6(R2) Section 4.13 requires the investigator/institution to provide the IRB/IEC with a summary of the trial’s outcome upon completion, and to send any required reports to the applicable regulatory authority(ies) — the COV is where a site typically confirms that notification has happened or is scheduled, even though the underlying obligation to notify the IRB/REB sits with the investigator/institution, not the monitor.
What triggers a close-out visit
A COV is triggered one of two ways. Most commonly, it follows a site’s own LPLV — once its last enrolled participant completes final follow-up, the site has no further protocol-required activity and is ready for close-out, generally on a timeline the sponsor’s monitoring plan specifies (commonly a defined window of weeks after LPLV, though ICH E6 itself sets no fixed number). Less commonly, a COV is triggered by early termination — of the whole trial (e.g., a data monitoring committee recommendation for futility or safety, sponsor business decision) or of a single site’s participation (e.g., a serious protocol deviation, an investigator leaving the institution, an IRB/REB withdrawal of approval). Early termination compresses the timeline but does not reduce the scope: the same query-resolution, IP-disposition, essential-document, and IRB-notification elements still apply.
Close-out visit vs. the rest of the site-visit lifecycle
The COV is the last of the recognized clinical monitoring visit types — pre-study/site-selection visit, Site Initiation Visit (SIV) (which confirms the site is ready to begin), the recurring Interim Monitoring Visit (IMV) (which confirms ongoing conduct while participants are actively enrolled or followed), and then the COV. It is distinguished from an IMV not by which checklist items it covers — both can touch source data, IP accountability, and document currency — but by timing and finality: a COV happens once, after the site’s last protocol-required activity, and it is the visit that formally closes the file rather than confirming ongoing compliance. See the Clinical Trial Monitoring guide for how COV fits alongside the other visit types and the broader monitoring plan.
Related terms
Site Initiation Visit (SIV), Interim Monitoring Visit (IMV), Trial Master File (TMF), Source Data Verification (SDV), Investigational Product (IP), Contract Research Organization (CRO).
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Close-Out Visit (COV)"
vocab-term-identifier="https://casrai.org/dictionary/term/close-out-visit-cov" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/close-out-visit-cov",
"name": "Close-Out Visit (COV)",
"identifier": "https://casrai.org/dictionary/term/close-out-visit-cov",
"description": "A Close-Out Visit (COV) is the final monitoring visit a sponsor or its Clinical Research Associate (CRA) conducts at a clinical trial site after the site has finished its participation in a study -- either because the site reached its last participant's last visit (LPLV) or because the trial or the site's participation was terminated early. A monitoring visit qualifies as a COV, rather than a routine Interim Monitoring Visit (IMV), only when it is the final visit for that site and confirms four things together: all outstanding data queries are resolved (or an agreed plan exists for any that cannot be), all required essential documents are complete and filed in the Trial Master File (TMF), investigational product (IP) has been reconciled and, per protocol/sponsor instruction, returned or destroyed with documentation, and the investigator/institution has notified (or is arranging to notify) the IRB/REB of study closure at that site.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
"url": "https://casrai.org/dictionary/term/close-out-visit-cov",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-23T05:59:10",
"inLanguage": "en"
}
